Showing 7271-7280 of 8897 results for "".
- Vial Welcomes David Pariser, MD to its Boardhttps://practicaldermatology.com/news/vial-welcomes-david-pariser-md-to-its-board/2461105/David Pariser, MD has joined the Vial Scientific Advisory Board. The Senior Physician at Pariser Dermatology Specialists, Dr. Pariser will share the Vial CRO team and sponsors his knowledge and insights from more than 40 years as a practicing dermatologist. The
- PCA SKIN® Recognizes Third Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-recognizes-third-annual-national-peel-day/2461104/PCA SKIN® wants to know #HowYouPeelin, as the company celebrates the third annual National Peel Day, Thursday, highlighting their latest peel innovation, new partnership, special promotion for accounts, and a host of social media activities.&
- Nancy Beesley Joins Dermavant Board of Directorshttps://practicaldermatology.com/news/nancy-beesley-joins-dermavant-board-of-directors/2461101/Nancy Beesley has been appointed to Dermavant Sciences’ Board of Directors. She joins Dermavant with more than 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurologica
- P&G Ventures Reintroduces Bodewell Line for Eczema and Psoriasishttps://practicaldermatology.com/news/pg-ventures-reintroduces-bodewell-line-for-eczema-and-psoriasis/2461098/P&G Ventures is reintroducing Bodewell, a line of skin care products for people with eczema and psoriasis. Bodewell’s new eczema and psoriasis lines feature actives like Colloidal Oatmeal and Salicylic Acid along with essential moisturizers and a novel botanical blend ca
- Successful Topline Results Seen for Hallura's New BiOLinkMatrix HA Aesthetic Fillershttps://practicaldermatology.com/news/successful-topline-results-seen-for-halluras-new-biolinkmatrix-ha-aesthetic-fillers/2461096/Hallura Ltd’s hyaluronic acid (HA) dermal fillers with its proprietary BiOLinkMatrix platform performed well for lip enhancement, nasolabial folds correction. and cheek enhancement, according to topline results. The proprietary Bi
- Vial Names Dr. Mark Lebwohl to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-names-dr-mark-lebwohl-to-scientific-advisory-board/2461091/The Vial Dermatology CRO has added Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board. Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.<
- US Senate Passes Dr. Lorna Breen Acthttps://practicaldermatology.com/news/us-senate-passes-lorna-breen-act/2461090/The US Senate has passed the bipartisan Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667). The bill previously was passed by the US House of Representatives, and now goes to President Biden to be signed into law. Once signed, the Dr. Lorna Breen Health Care
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als
- Business News: Taro to Acquire Alchemee From Galdermahttps://practicaldermatology.com/news/business-news-taro-to-acquire-alchemee-from-galderma/2461087/Taro Pharmaceutical Industries Ltd. Is buying Alchemee, formerly The Proactiv Company, from Galderma. The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed. "We are exc
- Study Establishes Optimal Drug Delivery Settings for Needle-free Jet Injectorshttps://practicaldermatology.com/news/study-establishes-optimal-drug-delivery-settings-for-needle-free-jet-injectors/2461085/Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not